NCT05644951已完成不适用
A Prospective, Multi-center, Single-arm Study for Unresectable Malignant Gastric Outlet Obstruction With EUS-guided Double-balloon-occluded Gastrojejunostomy Bypass
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 51
- 试验地点
- 12
- 主要终点
- GOOSS 3 rate without MAE
研究概览
简要总结
A prospective, multi-center, single-arm study for unresectable malignant gastric outlet obstruction with EUS-guided double-balloon-occluded gastrojejunostomy bypass (EPASS)
详细描述
Primary objective is to investigate the safety and effectiveness of the AXIOS™ lumen-apposing Metal Stent used in the EUS-guided double-balloon-occluded gastrojejunostomy bypass (EPASS) for the management of symptoms associated with gastric outlet obstruction (GOO) secondary to malignant unresectable neoplasm.
Primary Endpoint is GOOSS 3 rate without MAE at 30 days post procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unresectable malignant duodenal obstruction confirmed by biopsy
- •Eligible for endoscopic intervention
- •GOOSS score of 0 or 1
- •18 years of age or older
- •Willing and able to comply with the study procedures or legally authorized representative (LAR) must provide written informed consent form (ICF) to participate in the study
排除标准
- •GOO symptoms are not expected to improve after the index procedure
- •Life expectancy is about 3 months or less, which is not assumed applicable for surgical GJ
- •Prior metallic stent placement for GOO
- •Contraindicated to surgery and general anesthesia
- •Neoplasm invading the target site of puncture in gastric and/or jejunum
- •Abnormal coagulation INR > 1.5 and not correctable (per the discretion of the physician) or who require continuous complete anticoagulation
- •Bleeding diathesis
- •Altered anatomy of the upper gastrointestinal tract due to surgery of esophagus, stomach and duodenum that might preclude endoscopic drainage
- •Presence of ileus caused by peritoneal carcinomatosis, or expected to present within 30 days post procedure
- •Intervening gastric varices or vessels at the target site of stent insertion
- •Ascites that may interfere the safety of the index procedure
- •Biliary tract obstruction requiring treatment at the same day of the index procedure
- •Allergic to any of the device materials
- •Contraindications to use of electrosurgical devices
- •Pregnancy, breastfeeding or intending to become pregnant during the study period
- •Subject is currently participating, or plans to participate in, another investigational trial that may confound the results of this trial (unless written approval is received from the study sponsor)
- •Vulnerable subject
- •Subject has other reason not to be eligible for this study per investigators' discretion
- •Guidewire doesn't cross the area of GOO
- •EP-DB doesn't advance to the target site in jejunum
- •The distance between the gastric wall and jejunal wall when visualized on ultrasound after saline is introduced into the space between the two inflated balloons of EP-DB is deemed about 2 cm or more
结局指标
主要结局
GOOSS 3 rate without MAE
时间窗: 30 days post index-procedure
GOOSS 3 rate without MAE
次要结局
未报告次要终点
研究者
研究点 (12)
Loading locations...
相似试验
尚未招募
不适用
EUS-guided Versus Laparoscopic Gastrojejunostomy for Malignant Gastric Outlet ObstructionGastric Outlet ObstructionNCT05605327Universitaire Ziekenhuizen KU Leuven120
已完成
不适用
Gastric Outlet Obstructions Tailored Covered Stents for GOOGastric Outlet ObstructionNCT02299258The First People's Hospital of Yuhang District63
已完成
不适用
Preoperative and Postoperative Endoscopic Alterations in Patients Submitted to Gastric Bypass Without a RingObesityNCT03106207Kaiser Clinic and Hospital30
已完成
3 期
Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet ObstructionGastric Outlet Obstruction Due to Gastric AdenocarcinomaNCT01646476Samsung Medical Center102
招募中
不适用
Management of Malignant Gastric Outlet Obstruction Between Surgery and EndoscopyGastric Outlet ObstructionPancreatic CancerNCT06071507IRCCS San Raffaele250